From the hypotheses to clinical evidence in retinal therapy

Bradley Beatson, Fernando Arevalo

Research output: Contribution to journalReview articlepeer-review

Abstract

The off-label, therapeutic use of intravitreal bevacizumab (IVB) in vascular retinal diseases such as diabetic macular edema and proliferative diabetic retinopathy (PDR) has increased significantly due to its ability to reduce retinal neovascularization and slow progression of disease. Here, we will review the literature and investigative developments on the use of IVB as a preoperative adjuvant to vitrectomy in severe PDR, specifically focusing on its ability to reduce intra- A nd postoperative complications and its risk for progression or development of traction retinal detachment. In particular, this review will highlight the natural progression of evidence from case series and observations to prospective, randomized clinical trials

Original languageEnglish (US)
Pages (from-to)287-290
Number of pages4
JournalJournal of Ophthalmic and Vision Research
Volume16
Issue number2
DOIs
StatePublished - Apr 2021

Keywords

  • Diabetic macular edema
  • Diabetic retinopathy
  • Intravitreal bevacizumab
  • Tractional retinal detachment
  • Vascular endothelial growth factor
  • Vitrectomy

ASJC Scopus subject areas

  • Ophthalmology

Fingerprint

Dive into the research topics of 'From the hypotheses to clinical evidence in retinal therapy'. Together they form a unique fingerprint.

Cite this